Non-alcoholic fatty liver disease and women's health
DOI: 10.32364/2587-6821-2023-7-5-9
M.A. Livzan, M.I. Syrovenko, T.S. Krolevets
Omsk State Medical University, Omsk, Russian Federation
This article is aimed to summarize data on the incidence and patterns of the non-alcoholic fatty liver disease (NAFLD) course among women of different age. The prevalence of NAFLD is growing worldwide. In general, the incidence of this liver disease in men is higher than in women. However, a detailed examination of various age groups revealed that in women of reproductive age, the NAFLD incidence was lower than in men; at the same time, after menopause, the disease incidence in women became equal to the incidence in men, even exceeded it according to some data. Ongoing epidemiological, clinical and experimental studies indicate a higher risk of NAFLD and liver fibrosis in women with postmenopause versus woman with premenopause, as well as that older women with NAFLD have a higher mortality rate than men. One of the key roles in metabolic changes that contribute, in particular, to the NAFLD development is assigned to estrogens. The relevance of the NAFLD detection and treatment in women is due to a significantly higher prevalence of age-adjusted cardiovascular diseases, 5-year mortality from all causes and 5-year cardiovascular mortality versus women without NAFLD.
Keywords: non-alcoholic fatty liver disease, fibrosis, steatosis, menopause, premenopause, pregnancy, estrogens, ursodeoxycholic acid.
For citation: Livzan M.A., Syrovenko M.I., Krolevets T.S. Non-alcoholic fatty liver disease and women's health. Russian Medical Inquiry. 2023;7(5):310–317 (in Russ.). DOI: 10.32364/2587-6821-2023-7-5-9.
About the authors:
Maria A. Livzan — Dr. Sc. (Med.), Professor, Corresponding Member of the RAS, Head of the Department of Faculty Therapy and Gastroenterology, rector, Omsk State Medical University; 12, Lenin str., Omsk, 644099, Russian Federation; ORCID iD 0000-0002-6581-7017.
Maria I. Syrovenko — postgraduate student of the Department of Faculty Therapy and Gastroenterology, Omsk State Medical University; 12, Lenin str., Omsk, 644099, Russian Federation; ORCID iD 0000-0001-6300-367X.
Tatyana S. Krolevets — C. Sc. (Med.), associate professor of the Department of Faculty Therapy and Gastroenterology, Omsk State Medical University; 12, Lenin str., Omsk, 644099, Russian Federation; ORCID iD 0000-0002-7452-7230.
Contact information: Maria I. Syrovenko, e-mail: mariapli@yandex.ru.
Financial Disclosure: no authors have a financial or property interest in any material or method mentioned.
There is no conflict of interests.
Received 29.03.2023.
Revised 21.04.2023.
Accepted 19.05.2023.
References
1. Le M.H., Yeo Y.H., Li X. et al. 2019 Global NAFLD Prevalence: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2022;20(12):2809–2817.e28. DOI: 10.1016/j.cgh.2021.12.002.
2. Ballestri S., Nascimbeni F., Baldelli E. et al. NAFLD as a Sexual Dimorphic Disease: Role of Gender and Reproductive Status in the Development and Progression of Nonalcoholic Fatty Liver Disease and Inherent Cardiovascular Risk. Adv Ther. 2017;34(6):1291–1326. DOI: 10.1007/s12325-017-0556-1.
3. Riazi K., Azhari H., Charette J.H. et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2022;7:851–861. DOI: 10.1016/S2468-1253(22)00165-0.
4. Vernon G., Baranova A., Younossi Z.M. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011;34:274–285. DOI: 10.1111/j.1365-2036.2011.04724.x.
5. Драпкина О.М., Ивашкин В.Т. Эпидемиологические особенности неалкогольной жировой болезни печени в России (Результаты открытого многоцентрового проспективного исследования наблюдения DIREG L 01903). Российский журнал гастроэнтерологии, гепатологии и колопроктологии. 2014;24(4):32–38. [Drapkina O.M., Ivashkin V.T. Epidemiological features of non-alcoholic fatty liver disease in Russia (Results of an open multicenter prospective observational study DIREG L 01903). Russian Journal of Gastroenterology, Hepatology and Coloproctology. 2014;24(4):32–38 (in Russ.)].
6. Maev I.V., Samsonov A.A., Lazebnik L.B. et al. A New, Non-Invasive Scale for Steatosis Developed Using Real-World Data From 123 Russian Outpatients to Aid in the Diagnosis of Non-Alcoholic Fatty Liver Disease. Adv Ther. 2020;37(11):4627–4640. DOI: 10.1007/s12325-020-01493-w.
7. Younossi Z.M., Blissett D., Blissett R. et al. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe. Hepatology. 2016;64(5):1577–1586. DOI: 10.1002/hep.28785.
8. Estes C., Razavi H., Loomba R. et al. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology. 2018;67(1):123–133. DOI: 10.1002/hep.29466.
9. Arshad T., Golabi P., Paik J. et al. Prevalence of nonalcoholic fatty liver disease in the female population. Hepatol Commun. 2019;3(1):74–83. DOI: 10.1002/hep4.1285.
10. Paik J.M., Henry L., De Avila L. et al. Mortality related to nonalcoholic fatty liver disease is increasing in the United States. Hepatol Commun. 2019:3(11):1459–1471. DOI: 10.1002/hep4.1419.
11. Noureddin M., Vipani A., Bresee C. et al. NASH leading cause of liver transplant in women: updated analysis of indications for liver transplant and ethnic and gender variances. Am J Gastroenterol. 2018;113(11):1649–1659. DOI: 10.1038/s41395-018-0088-6.
12. Wang Z., Xu M., Hu Z. et al. Sex-specific prevalence of fatty liver disease and associated metabolic factors in Wuhan, south central China. Eur J Gastroenterol Hepatol. 2014;26:1015–1021. DOI: 10.1097/MEG.0000000000000151.
13. Singh D.K., Sakhuja P., Malhotra V. et al. Independent predictors of steatohepatitis and fibrosis in Asian Indian patients with non-alcoholic steatohepatitis. Dig Dis Sci. 2008;53:1967-1976. DOI: 10.1007/s10620-007-0074-0.
14. Bambha K., Belt P., Abraham M. et al. Ethnicity and nonalcoholic fatty liver disease. Hepatology. 2012;55:769–780. DOI: 10.1002/hep.24726.
15. Tapper E.B., Krajewski K., Lai M. et al. Simple non-invasive biomarkers of advanced fibrosis in the evaluation of non-alcoholic fatty liver disease. Gastroenterol Rep (Oxf). 2014;2:276–280. DOI: 10.1093/gastro/gou034.
16. Sayaf K., Gabbia D., Russo F.P., De Martin S. The Role of Sex in Acute and Chronic Liver Damage. Int J Mol Sci. 2022;23(18):10654. DOI: 10.3390/ijms231810654.
17. Hamaguchi M., Kojima T., Ohbora A. et al. Aging is a risk factor of nonalcoholic fatty liver disease in premenopausal women. World J Gastroenterol. 2012;18:237–243. DOI: 10.3748/wjg.v18.i3.237.
18. Suzuki A., Diehl A.M. Nonalcoholic steatohepatitis. Annu Rev Med. 2017;68:85–98. DOI: 10.1146/annurev-med-051215-031109.
19. Burra P., Bizzaro D., Gonta A. et al.; the Special Interest Group Gender in Hepatology of the Italian Association for the Study of the Liver (AISF). Clinical impact of sexual dimorphism in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Liver Int. 2021;41:1713–1733. DOI: 10.1111/liv.14943.
20. Shen M., Shi H. Sex Hormones and Their Receptors Regulate Liver Energy Homeostasis. Int J Endocrinol. 2015;2015:294278. DOI: 10.1155/2015/294278.
21. Kley H.K., Kruskemper H.L., Keck E. Estrone and estradiol in patients with cirrhosis of the liver: Effects of ACTH and dexamethasone. J Clin Endocrinol Metab. 1976;43:557–560. DOI: 10.1210/jcem-43-3-557.
22. Wang H., Eriksson H.K., Sahlin L. Estrogen receptors alpha and beta in the female reproductive tract of the rat during the estrous cycle. Biol Reprod. 2000;63:1331–1340. DOI: 10.1095/biolreprod63.5.1331.
23. Speirs V., Skliris G.P., Burdall S.E., Carder P.J. Distinct expression patterns of ER alpha and ER beta in normal human mammary gland. J Clin Pathol. 2002;55:371–374. DOI: 10.1136/jcp.55.5.371.
24. Zhou Y., Shimizu I., Lu G. et al. Hepatic stellate cells contain the functional estrogen receptor beta but not the estrogen receptor alpha in male and female rats. Biochem Biophys Res Commun. 2001;286:1059–1065. DOI: 10.1006/bbrc.2001.5479.
25. Palmisano B.T., Zhu L., Stafford J.M. Role of Estrogens in the Regulation of Liver Lipid Metabolism. Adv Exp Med Biol. 2017;1043:227–256. DOI: 10.1007/978-3-319-70178-3_12.
26. Yu C.P., Ho J.Y., Huang Y.T. et al. Estrogen inhibits renal cell carcinoma cell progression through estrogen receptor-beta activation. PLoS One. 2013;8(2):e56667. DOI: 10.1371/journal.pone.0056667.
27. Hinsche O., Girgert R., Emons G., Grundker C. Estrogen receptor beta selective agonists reduce invasivenessof triple-negative breast cancer cells. Int J Oncol. 2015;46:878–884. DOI: 10.3892/ijo.2014.2778.
28. Kuiper G.G., Carlsson B., Grandien K. et al. Comparisonof the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology. 1997;138:863–870. DOI: 10.1210/endo.138.3.4979.
29. Barton M. Cholesterol andatherosclerosis: modulation by oestrogen. Curr Opin Lipidol. 2013;24:214–220. DOI: 10.1097/MOL.0b013e3283613a94.
30. Feingold K.R. The Effect of Endocrine Disorders on Lipids and Lipoproteins. 2023 Apr 6. In: Feingold K.R., Anawalt B., Blackman M.R. et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000. PMID: 28121116.
31. Monteiro R., Teixeira D., Calhau C. Estrogen signaling in metabolic inflammation. Mediators Inflamm. 2014;2014:615917. DOI: 10.1155/2014/615917.
32. Tian G.X., Sun Y., Pang C.J. et al. Oestradiol is a protective factor for non-alcoholic fatty liver disease in healthy men. Obes Rev. 2012;13:381–387. DOI: 10.1111/j.1467-789X.2011.00978.x.
33. Paquette A., Wang D., Jankowski M. et al. Effects of ovariectomy on PPAR alpha, SREBP-1c, and SCD-1 gene expression in the rat liver. Menopause. 2008;15:1169–1175. DOI: 10.1097/gme.0b013e31817b8159.
34. Mueller N.T., Pereira M.A., Demerath E.W. et al. Earlier menarche is associated with fatty liver and abdominal ectopic fat in midlife, independent of young adult. BMI: the CARDIA study. Obesity (Silver Spring). 2015;23:468–474. DOI: 10.1002/oby.20950.
35. Cho I.Y., Chang Y., Kang J.H. et al. Long or Irregular Menstrual Cycles and Risk of Prevalent and Incident Nonalcoholic Fatty Liver Disease. J Clin Endocrinol Metab. 2022;107(6):e2309–e2317. DOI: 10.1210/clinem/dgac068.
36. Ивашкин В.Т., Маевская М.В., Жаркова М.С. и др. Клинические рекомендации Российского общества по изучению печени, Российской гастроэнтерологической ассоциации, Российской ассоциации эндокринологов, Российской ассоциации геронтологов и гериатров и Национального общества профилактической кардиологии по диагностике и лечению неалкогольной жировой болезни печени. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2022;32(4):104–140. DOI: 10.22416/1382-4376-2022-32-4-104-140. [Ivashkin V.T., Maevskaya M.V., Zharkova M.S. et al. Clinical Practice Guidelines of the Russian Scientific Liver Society, Russian Gastroenterological Association, Russian Association of Endocrinologists, Russian Association of Gerontologists and Geriatricians and National Society for Preventive Cardiology on Diagnosis and Treatment of Non-Alcoholic Liver Disease. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2022;32(4):104–140 (in Russ.)]. DOI: 10.22416/1382-4376-2022-32-4-104-140.
37. Haukeland J.W., Damas J.K., Konopski Z. et al. Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2. J Hepatol. 2006;44:1167–1174. DOI: 10.1016/j.jhep.2006.02.011.
38. Turola E., Petta S., Vanni E. et al. Ovarian senescence increases liver fibrosis in humans and zebrafish with steatosis. Dis Model Mech. 2015;8:1037–1046. DOI: 10.1242/dmm.019950.
39. Xin G., Qin S., Wang S. et al. Sex hormone affects the severity of non-alcoholic steatohepatitis through the MyD88-dependent IL-6 signaling pathway. Exp Biol Med. 2015;240:1279–1286. DOI: 10.1177/1535370215570189.
40. Aldhoon-Hainerova I., Zamrazilova H., Hill M. et al. Insulin sensitivity and its relation to hormones in adolescent boys and girls. Metabolism. 2017;67:90–98. DOI: 10.1016/j.metabol.2016.10.005.
41. Taraborrelli S. Physiology, production and action of progesterone. Acta Obstet Gynecol Scand. 2015;94(Suppl 161):8–16. DOI: 10.1111/aogs.12771.
42. La Colla A., Pronsato L., Milanesi L. et al. 17b-Estradiol and testosterone in sarcopenia: role of satellite cells. Ageing Res Rev. 2015;24:166–177. DOI: 10.1016/j.arr.2015.07.01.
43. Rocha A.L.L., Faria L.C., Guimarães T.C.M. et al. Non-alcoholic fatty liver disease in women with polycystic ovary syndrome: Systematic review and meta-analysis. J Endocrinol Investig. 2017;40:1279–1288. DOI: 10.1007/s40618-017-0708-9.
44. Shahbaz M., Almatooq H., Foucambert P. et al. A Systematic Review of the Risk of Non-alcoholic Fatty Liver Disease in Women With Polycystic Ovary Syndrome. Cureus. 2022;14(10):e29928. DOI: 10.7759/cureus.29928.
45. Shengir M., Chen T., Guadagno E. et al. Non-alcoholic fatty liver disease in premenopausal women with polycystic ovary syndrome: A systematic review and meta-analysis. JGH Open. 2021;5:434–445. DOI: 10.1002/jgh3.12512.
46. Sarkar M., Terrault N., Chan W. et al. Polycystic ovary syndrome (PCOS) is associated with NASH severity and advanced fibrosis. Liver Int. 2020;40:355–359. DOI: 10.1111/liv.14279.
47. McDonnell T., Cussen L., McIlroy M., O'Reilly M.W. Characterizing skeletal muscle dysfunction in women with polycystic ovary syndrome. Ther Adv Endocrinol Metab. 2022;13:20420188221113140. DOI: 10.1177/20420188221113140.
48. Song M.J., Choi J.Y. Androgen dysfunction in non-alcoholic fatty liver disease: Role of sex hormone binding globulin. Front Endocrinol (Lausanne). 2022;13:1053709. DOI: 10.3389/fendo.2022.1053709.
49. Shimizu I., Mizobuchi Y., Yasuda M. et al. Inhibitory effect of oestradiol on activation of rat hepatic stellate cells In Vivo and In Vitro. Gut. 1999;44:127–136. DOI: 10.1136/gut.44.1.127.
50. Liu Q.H., Li D.G., Huang X. et al. Suppressive effects of 17beta-estradiol on hepatic fibrosis in CCl4-induced rat model. World J Gastroenterol. 2004;10:1315–1320. DOI: 10.3748/wjg.v10.i9.1315.
51. Zhang B., Zhang C.G., Ji L.H. et al. Estrogen receptor selective agonist ameliorates liver cirrhosis in rats by inhibiting the activation and proliferation of hepatic stellate cells. J Gastroenterol Hepatol. 2018;33:747–755. DOI: 10.1111/jgh.13976.
52. Tobari M., Hashimoto E., Taniai M. et al. Characteristics of non-alcoholic steatohepatitis among lean patients in Japan: Not uncommon and not always benign. J Gastroenterol Hepatol. 2019;34:1404–1410. DOI: 10.1111/jgh.14585.
53. Yang J.D., Abdelmalek M.F., Pang H. et al. Gender andmenopause impact severity of fibrosis among patients with nonalcoholic steatohepatitis. Hepatology. 2014;59:1406–1414. DOI: 10.1002/hep.26761.
54. Hershman M., Mei R., Kushner T. Implications of nonalcoholic fatty liver disease on pregnancy and maternal and child outcomes. Gastroenterol Hepatol (N Y). 2019;15:221–228. PMID: 31435201.
55. El Jamaly H., Eslick G.D., Weltman M. Systematic review with meta-analysis: Non-alcoholic fatty liver disease and the association with pregnancy outcomes. Clin Mol Hepatol. 2022;28(1):52–66. DOI: 10.3350/cmh.2021.0205.
56. Sarkar M., Djerboua M., Flemming J.A. NAFLD Cirrhosis Is Rising Among Childbearing Women and Is the Most Common Cause of Cirrhosis in Pregnancy. Clin Gastroenterol Hepatol. 2022;20(2):e315–e318. DOI: 10.1016/j.cgh.2021.01.022.
57. Sarkar M., Brady C.W., Fleckenstein J. et al. Reproductive Health and Liver Disease: Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2021;73(1):318–365. DOI: 10.1002/hep.31559.
58. Shulman G.I. Ectopic fat in insulin resistance, dyslipidemia, and cardiometabolic disease. N Engl J Med. 2014;371:1131–1141. DOI: 10.1056/NEJMra1011035.
59. Friedman G.D., Cutter G.R., Donahue R.P. et al. CARDIA: study design, recruitment, and some characteristics of the examined subjects. J Clin Epidemiol. 1988;41:1105–1116. DOI: 10.1016/0895-4356(88)90080-7.
60. De Souza L.R., Berger H., Retnakaran R. et al. Non-alcoholic fatty liver disease in early pregnancy predicts dysglycemia in mid-pregnancy: prospective study. Am J Gastroenterol. 2016;111:665–670. DOI: 10.1038/ajg.2016.43.
61. Bjornsson E.S., Bergmann O.M., Bjornsson H.K. et al. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology. 2013;144(7):1419–1425, 1425.e1-3; quiz e19-20. DOI: 10.1053/j.gastro.2013.02.006.
62. National Institute of Diabetes and Digestive and Kidney Diseases. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases; Updated May 28, 2020.
63. Tobari M., Hashimoto E. Characteristic Features of Nona/lcoholic Fatty Liver Disease in Japan with a Focus on the Roles of Age, Sex and Body Mass Index. Gut Liver. 2020;14(5):537–545. DOI: 10.5009/gnl19236.
64. Arshad T., Golabi P., Paik J. et al. Prevalence of nonalcoholic fatty liver disease in the female population. Hepatol Commun. 2019;3(1):74–83. DOI: 10.1002/hep4.1285.
65. Santos-Marcos J.A., Rangel-Zuniga O.A., Jimenez-Lucena R. et al. Influence of gender and menopausal status on gut microbiota. Maturitas. 2018;116:43–53. DOI: 10.1016/j.maturitas.2018.07.008.
66. Liu Y., Lu J., Xu M. et al. Association between history of abortion and nonalcoholic fatty liver disease in middle-aged and elderly Chinese women. Ann Epidemiol. 2013;23:119–123. DOI: 10.1016/j.annepidem.2012.12.002.
67. Ajmera V., Terrault N.A., VanWagner L. et al. Longer lactation duration is associated with decreased prevalence of non-alcoholic fatty liver disease in women. J Hepatol. 2019;70:126–132. DOI: 10.1016/j.jhep.2018.09.013.
68. Hamaguchi M., Kojima T., Takeda N. et al. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med. 2005;143:722–728. DOI: 10.7326/0003-4819-143-10-200511150-00009.
69. Kojima S., Watanabe N., Numata M. et al. Increase in the prevalence of fatty liver in Japan over the past 12 years: Analysis of clinical background. J Gastroenterol. 2003;38:954–961. DOI: 10.1007/s00535-003-1178-8.
70. Park S.H., Jeon W.K., Kim S.H. et al. Prevalence and risk factors of non-alcoholic fatty liver disease among Korean adults. J Gastroenterol Hepatol. 2006;21:138–143. DOI: 10.1111/j.1440-1746.2005.04086.x.
71. Zhou Y.J., Li Y.Y., Nie Y.Q. et al. Prevalence of fatty liver disease and its risk factors in the population of South China. World J Gastroenterol. 2007:13:6419–6424. DOI: 10.3748/wjg.v13.i47.6419.
72. Koulouri O., Ostberg J., Conway G.S. Liver dysfunction in Turner's syndrome: Prevalence, natural history and e_ect of exogenous oestrogen. Clin Endocrinol (Oxf.) 2008;69:306–310. DOI: 10.1111/j.1365-2265.2008.03203.x.
73. Ascha M.S., Hanouneh I.A., Lopez R. et al. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology. 2010;51:1972–1978. DOI: 10.1002/hep.23527.
74. Klair J.S., Yang J.D., Abdelmalek M.F. et al. A longer duration of estrogen deficiency increases fibrosis risk among postmenopausal women with nonalcoholic fatty liver disease. Hepatology. 2016;64:85–91. DOI: 10.1002/hep.28514.
75. Lee C., Kim J., Jung Y. Potential Therapeutic Application of Estrogen in Gender Disparity of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis. Cells. 2019;8(10):1259. DOI: 10.3390/cells8101259.
76. Yoneda M., Thomas E., Sumida Y. et al. The influence of menopause on the development of hepatic fibrosis in nonobese women with nonalcoholic fatty liver disease. Hepatology. 2014;60:1792. DOI: 10.1002/hep.27097.
77. Klair J.S., Yang J.D., Abdelmalek M.F. et al. Nonalcoholic Steatohepatitis Clinical Research Network. A longer duration of estrogen deficiency increases fibrosis risk among postmenopausal women with nonalcoholic fatty liver disease. Hepatology. 2016;64(1):85–91. DOI: 10.1002/hep.28514.
78. European Heart Network. European Cardiovascular Disease Statistics 2017 edition. Brussels, Belgium: European Heart Network, 2017. DOI: 10.21820/23987073.2017.6.56.
79. Maas A.H.E.M., Rosano G., Cifkova R. et al. Cardiovascular health after menopause transition, pregnancy disorders, and other gynaecologic conditions: a consensus document from European Cardiologists, Gynaecologists, and Endocrinologists. Eur Heart J. 2021;42:967–984. DOI: 10.1093/eurheartj/ehaa1044.
80. Stevenson J.C., Collins P., Hamoda H. et al. Cardiometabolic health in premature ovarian insufficiency. Climacteric. 2021;24:474–480. DOI: 10.1080/13697137.2021.1910232.
81. Anagnostis P., Lambrinoudaki I., Stevenson J.C., Goulis D.G. Menopause-associated risk of cardiovascular disease. Endocr Connect. 2022;11(4):e210537. DOI: 10.1530/EC-21-0537.
82. Nadinskaia M., Maevskaya M., Ivashkin V. et al. Ursodeoxycholic acid as a means of preventing atherosclerosis, steatosis and liver fibrosis in patients with nonalcoholic fatty liver disease. World J Gastroenterol 2021;27(10):959–975. DOI: 10.3748/wjg.v27.i10.959.
83. Гаврилова Н.П., Селивёрстов П.В., Айрапетян М.С. и др. Урсодезоксихолевая кислота в комбинации с менопаузальной гормональной терапией корригирует метаболические нарушения у женщин в менопаузе с неалкогольной жировой болезнью печени. Экспериментальная и клиническая гастроэнтерология. 2019;168(8):77–81. DOI: 10.31146/1682-8658-ecg-168-8-77-81. [Gavrilova N.P., Seliverstov P.V., Ayrapetyan M.S. et al. Ursodeoxycholic acid in combination with menopausal hormone therapy corrects metabolic abnormalities in postmenopausal women with non-alcoholic fatty liver disease. Experimental and Clinical Gastroenterology. 2019;168(8):77–81 (in Russ.)]. DOI: 10.31146/1682-8658-ecg-168-8-77-81.
84. Gozukara I., Dokuyucu R., Özgür T. et al. Histopathologic and metabolic effect of ursodeoxycholic acid treatment on PCOS rat model. Gynecol Endocrinol. 2016;32(6):492–497. DOI: 10.3109/09513590.2015.1134478.
2. Ballestri S., Nascimbeni F., Baldelli E. et al. NAFLD as a Sexual Dimorphic Disease: Role of Gender and Reproductive Status in the Development and Progression of Nonalcoholic Fatty Liver Disease and Inherent Cardiovascular Risk. Adv Ther. 2017;34(6):1291–1326. DOI: 10.1007/s12325-017-0556-1.
3. Riazi K., Azhari H., Charette J.H. et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2022;7:851–861. DOI: 10.1016/S2468-1253(22)00165-0.
4. Vernon G., Baranova A., Younossi Z.M. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011;34:274–285. DOI: 10.1111/j.1365-2036.2011.04724.x.
5. Драпкина О.М., Ивашкин В.Т. Эпидемиологические особенности неалкогольной жировой болезни печени в России (Результаты открытого многоцентрового проспективного исследования наблюдения DIREG L 01903). Российский журнал гастроэнтерологии, гепатологии и колопроктологии. 2014;24(4):32–38. [Drapkina O.M., Ivashkin V.T. Epidemiological features of non-alcoholic fatty liver disease in Russia (Results of an open multicenter prospective observational study DIREG L 01903). Russian Journal of Gastroenterology, Hepatology and Coloproctology. 2014;24(4):32–38 (in Russ.)].
6. Maev I.V., Samsonov A.A., Lazebnik L.B. et al. A New, Non-Invasive Scale for Steatosis Developed Using Real-World Data From 123 Russian Outpatients to Aid in the Diagnosis of Non-Alcoholic Fatty Liver Disease. Adv Ther. 2020;37(11):4627–4640. DOI: 10.1007/s12325-020-01493-w.
7. Younossi Z.M., Blissett D., Blissett R. et al. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe. Hepatology. 2016;64(5):1577–1586. DOI: 10.1002/hep.28785.
8. Estes C., Razavi H., Loomba R. et al. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology. 2018;67(1):123–133. DOI: 10.1002/hep.29466.
9. Arshad T., Golabi P., Paik J. et al. Prevalence of nonalcoholic fatty liver disease in the female population. Hepatol Commun. 2019;3(1):74–83. DOI: 10.1002/hep4.1285.
10. Paik J.M., Henry L., De Avila L. et al. Mortality related to nonalcoholic fatty liver disease is increasing in the United States. Hepatol Commun. 2019:3(11):1459–1471. DOI: 10.1002/hep4.1419.
11. Noureddin M., Vipani A., Bresee C. et al. NASH leading cause of liver transplant in women: updated analysis of indications for liver transplant and ethnic and gender variances. Am J Gastroenterol. 2018;113(11):1649–1659. DOI: 10.1038/s41395-018-0088-6.
12. Wang Z., Xu M., Hu Z. et al. Sex-specific prevalence of fatty liver disease and associated metabolic factors in Wuhan, south central China. Eur J Gastroenterol Hepatol. 2014;26:1015–1021. DOI: 10.1097/MEG.0000000000000151.
13. Singh D.K., Sakhuja P., Malhotra V. et al. Independent predictors of steatohepatitis and fibrosis in Asian Indian patients with non-alcoholic steatohepatitis. Dig Dis Sci. 2008;53:1967-1976. DOI: 10.1007/s10620-007-0074-0.
14. Bambha K., Belt P., Abraham M. et al. Ethnicity and nonalcoholic fatty liver disease. Hepatology. 2012;55:769–780. DOI: 10.1002/hep.24726.
15. Tapper E.B., Krajewski K., Lai M. et al. Simple non-invasive biomarkers of advanced fibrosis in the evaluation of non-alcoholic fatty liver disease. Gastroenterol Rep (Oxf). 2014;2:276–280. DOI: 10.1093/gastro/gou034.
16. Sayaf K., Gabbia D., Russo F.P., De Martin S. The Role of Sex in Acute and Chronic Liver Damage. Int J Mol Sci. 2022;23(18):10654. DOI: 10.3390/ijms231810654.
17. Hamaguchi M., Kojima T., Ohbora A. et al. Aging is a risk factor of nonalcoholic fatty liver disease in premenopausal women. World J Gastroenterol. 2012;18:237–243. DOI: 10.3748/wjg.v18.i3.237.
18. Suzuki A., Diehl A.M. Nonalcoholic steatohepatitis. Annu Rev Med. 2017;68:85–98. DOI: 10.1146/annurev-med-051215-031109.
19. Burra P., Bizzaro D., Gonta A. et al.; the Special Interest Group Gender in Hepatology of the Italian Association for the Study of the Liver (AISF). Clinical impact of sexual dimorphism in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Liver Int. 2021;41:1713–1733. DOI: 10.1111/liv.14943.
20. Shen M., Shi H. Sex Hormones and Their Receptors Regulate Liver Energy Homeostasis. Int J Endocrinol. 2015;2015:294278. DOI: 10.1155/2015/294278.
21. Kley H.K., Kruskemper H.L., Keck E. Estrone and estradiol in patients with cirrhosis of the liver: Effects of ACTH and dexamethasone. J Clin Endocrinol Metab. 1976;43:557–560. DOI: 10.1210/jcem-43-3-557.
22. Wang H., Eriksson H.K., Sahlin L. Estrogen receptors alpha and beta in the female reproductive tract of the rat during the estrous cycle. Biol Reprod. 2000;63:1331–1340. DOI: 10.1095/biolreprod63.5.1331.
23. Speirs V., Skliris G.P., Burdall S.E., Carder P.J. Distinct expression patterns of ER alpha and ER beta in normal human mammary gland. J Clin Pathol. 2002;55:371–374. DOI: 10.1136/jcp.55.5.371.
24. Zhou Y., Shimizu I., Lu G. et al. Hepatic stellate cells contain the functional estrogen receptor beta but not the estrogen receptor alpha in male and female rats. Biochem Biophys Res Commun. 2001;286:1059–1065. DOI: 10.1006/bbrc.2001.5479.
25. Palmisano B.T., Zhu L., Stafford J.M. Role of Estrogens in the Regulation of Liver Lipid Metabolism. Adv Exp Med Biol. 2017;1043:227–256. DOI: 10.1007/978-3-319-70178-3_12.
26. Yu C.P., Ho J.Y., Huang Y.T. et al. Estrogen inhibits renal cell carcinoma cell progression through estrogen receptor-beta activation. PLoS One. 2013;8(2):e56667. DOI: 10.1371/journal.pone.0056667.
27. Hinsche O., Girgert R., Emons G., Grundker C. Estrogen receptor beta selective agonists reduce invasivenessof triple-negative breast cancer cells. Int J Oncol. 2015;46:878–884. DOI: 10.3892/ijo.2014.2778.
28. Kuiper G.G., Carlsson B., Grandien K. et al. Comparisonof the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology. 1997;138:863–870. DOI: 10.1210/endo.138.3.4979.
29. Barton M. Cholesterol andatherosclerosis: modulation by oestrogen. Curr Opin Lipidol. 2013;24:214–220. DOI: 10.1097/MOL.0b013e3283613a94.
30. Feingold K.R. The Effect of Endocrine Disorders on Lipids and Lipoproteins. 2023 Apr 6. In: Feingold K.R., Anawalt B., Blackman M.R. et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000. PMID: 28121116.
31. Monteiro R., Teixeira D., Calhau C. Estrogen signaling in metabolic inflammation. Mediators Inflamm. 2014;2014:615917. DOI: 10.1155/2014/615917.
32. Tian G.X., Sun Y., Pang C.J. et al. Oestradiol is a protective factor for non-alcoholic fatty liver disease in healthy men. Obes Rev. 2012;13:381–387. DOI: 10.1111/j.1467-789X.2011.00978.x.
33. Paquette A., Wang D., Jankowski M. et al. Effects of ovariectomy on PPAR alpha, SREBP-1c, and SCD-1 gene expression in the rat liver. Menopause. 2008;15:1169–1175. DOI: 10.1097/gme.0b013e31817b8159.
34. Mueller N.T., Pereira M.A., Demerath E.W. et al. Earlier menarche is associated with fatty liver and abdominal ectopic fat in midlife, independent of young adult. BMI: the CARDIA study. Obesity (Silver Spring). 2015;23:468–474. DOI: 10.1002/oby.20950.
35. Cho I.Y., Chang Y., Kang J.H. et al. Long or Irregular Menstrual Cycles and Risk of Prevalent and Incident Nonalcoholic Fatty Liver Disease. J Clin Endocrinol Metab. 2022;107(6):e2309–e2317. DOI: 10.1210/clinem/dgac068.
36. Ивашкин В.Т., Маевская М.В., Жаркова М.С. и др. Клинические рекомендации Российского общества по изучению печени, Российской гастроэнтерологической ассоциации, Российской ассоциации эндокринологов, Российской ассоциации геронтологов и гериатров и Национального общества профилактической кардиологии по диагностике и лечению неалкогольной жировой болезни печени. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2022;32(4):104–140. DOI: 10.22416/1382-4376-2022-32-4-104-140. [Ivashkin V.T., Maevskaya M.V., Zharkova M.S. et al. Clinical Practice Guidelines of the Russian Scientific Liver Society, Russian Gastroenterological Association, Russian Association of Endocrinologists, Russian Association of Gerontologists and Geriatricians and National Society for Preventive Cardiology on Diagnosis and Treatment of Non-Alcoholic Liver Disease. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2022;32(4):104–140 (in Russ.)]. DOI: 10.22416/1382-4376-2022-32-4-104-140.
37. Haukeland J.W., Damas J.K., Konopski Z. et al. Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2. J Hepatol. 2006;44:1167–1174. DOI: 10.1016/j.jhep.2006.02.011.
38. Turola E., Petta S., Vanni E. et al. Ovarian senescence increases liver fibrosis in humans and zebrafish with steatosis. Dis Model Mech. 2015;8:1037–1046. DOI: 10.1242/dmm.019950.
39. Xin G., Qin S., Wang S. et al. Sex hormone affects the severity of non-alcoholic steatohepatitis through the MyD88-dependent IL-6 signaling pathway. Exp Biol Med. 2015;240:1279–1286. DOI: 10.1177/1535370215570189.
40. Aldhoon-Hainerova I., Zamrazilova H., Hill M. et al. Insulin sensitivity and its relation to hormones in adolescent boys and girls. Metabolism. 2017;67:90–98. DOI: 10.1016/j.metabol.2016.10.005.
41. Taraborrelli S. Physiology, production and action of progesterone. Acta Obstet Gynecol Scand. 2015;94(Suppl 161):8–16. DOI: 10.1111/aogs.12771.
42. La Colla A., Pronsato L., Milanesi L. et al. 17b-Estradiol and testosterone in sarcopenia: role of satellite cells. Ageing Res Rev. 2015;24:166–177. DOI: 10.1016/j.arr.2015.07.01.
43. Rocha A.L.L., Faria L.C., Guimarães T.C.M. et al. Non-alcoholic fatty liver disease in women with polycystic ovary syndrome: Systematic review and meta-analysis. J Endocrinol Investig. 2017;40:1279–1288. DOI: 10.1007/s40618-017-0708-9.
44. Shahbaz M., Almatooq H., Foucambert P. et al. A Systematic Review of the Risk of Non-alcoholic Fatty Liver Disease in Women With Polycystic Ovary Syndrome. Cureus. 2022;14(10):e29928. DOI: 10.7759/cureus.29928.
45. Shengir M., Chen T., Guadagno E. et al. Non-alcoholic fatty liver disease in premenopausal women with polycystic ovary syndrome: A systematic review and meta-analysis. JGH Open. 2021;5:434–445. DOI: 10.1002/jgh3.12512.
46. Sarkar M., Terrault N., Chan W. et al. Polycystic ovary syndrome (PCOS) is associated with NASH severity and advanced fibrosis. Liver Int. 2020;40:355–359. DOI: 10.1111/liv.14279.
47. McDonnell T., Cussen L., McIlroy M., O'Reilly M.W. Characterizing skeletal muscle dysfunction in women with polycystic ovary syndrome. Ther Adv Endocrinol Metab. 2022;13:20420188221113140. DOI: 10.1177/20420188221113140.
48. Song M.J., Choi J.Y. Androgen dysfunction in non-alcoholic fatty liver disease: Role of sex hormone binding globulin. Front Endocrinol (Lausanne). 2022;13:1053709. DOI: 10.3389/fendo.2022.1053709.
49. Shimizu I., Mizobuchi Y., Yasuda M. et al. Inhibitory effect of oestradiol on activation of rat hepatic stellate cells In Vivo and In Vitro. Gut. 1999;44:127–136. DOI: 10.1136/gut.44.1.127.
50. Liu Q.H., Li D.G., Huang X. et al. Suppressive effects of 17beta-estradiol on hepatic fibrosis in CCl4-induced rat model. World J Gastroenterol. 2004;10:1315–1320. DOI: 10.3748/wjg.v10.i9.1315.
51. Zhang B., Zhang C.G., Ji L.H. et al. Estrogen receptor selective agonist ameliorates liver cirrhosis in rats by inhibiting the activation and proliferation of hepatic stellate cells. J Gastroenterol Hepatol. 2018;33:747–755. DOI: 10.1111/jgh.13976.
52. Tobari M., Hashimoto E., Taniai M. et al. Characteristics of non-alcoholic steatohepatitis among lean patients in Japan: Not uncommon and not always benign. J Gastroenterol Hepatol. 2019;34:1404–1410. DOI: 10.1111/jgh.14585.
53. Yang J.D., Abdelmalek M.F., Pang H. et al. Gender andmenopause impact severity of fibrosis among patients with nonalcoholic steatohepatitis. Hepatology. 2014;59:1406–1414. DOI: 10.1002/hep.26761.
54. Hershman M., Mei R., Kushner T. Implications of nonalcoholic fatty liver disease on pregnancy and maternal and child outcomes. Gastroenterol Hepatol (N Y). 2019;15:221–228. PMID: 31435201.
55. El Jamaly H., Eslick G.D., Weltman M. Systematic review with meta-analysis: Non-alcoholic fatty liver disease and the association with pregnancy outcomes. Clin Mol Hepatol. 2022;28(1):52–66. DOI: 10.3350/cmh.2021.0205.
56. Sarkar M., Djerboua M., Flemming J.A. NAFLD Cirrhosis Is Rising Among Childbearing Women and Is the Most Common Cause of Cirrhosis in Pregnancy. Clin Gastroenterol Hepatol. 2022;20(2):e315–e318. DOI: 10.1016/j.cgh.2021.01.022.
57. Sarkar M., Brady C.W., Fleckenstein J. et al. Reproductive Health and Liver Disease: Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2021;73(1):318–365. DOI: 10.1002/hep.31559.
58. Shulman G.I. Ectopic fat in insulin resistance, dyslipidemia, and cardiometabolic disease. N Engl J Med. 2014;371:1131–1141. DOI: 10.1056/NEJMra1011035.
59. Friedman G.D., Cutter G.R., Donahue R.P. et al. CARDIA: study design, recruitment, and some characteristics of the examined subjects. J Clin Epidemiol. 1988;41:1105–1116. DOI: 10.1016/0895-4356(88)90080-7.
60. De Souza L.R., Berger H., Retnakaran R. et al. Non-alcoholic fatty liver disease in early pregnancy predicts dysglycemia in mid-pregnancy: prospective study. Am J Gastroenterol. 2016;111:665–670. DOI: 10.1038/ajg.2016.43.
61. Bjornsson E.S., Bergmann O.M., Bjornsson H.K. et al. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology. 2013;144(7):1419–1425, 1425.e1-3; quiz e19-20. DOI: 10.1053/j.gastro.2013.02.006.
62. National Institute of Diabetes and Digestive and Kidney Diseases. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases; Updated May 28, 2020.
63. Tobari M., Hashimoto E. Characteristic Features of Nona/lcoholic Fatty Liver Disease in Japan with a Focus on the Roles of Age, Sex and Body Mass Index. Gut Liver. 2020;14(5):537–545. DOI: 10.5009/gnl19236.
64. Arshad T., Golabi P., Paik J. et al. Prevalence of nonalcoholic fatty liver disease in the female population. Hepatol Commun. 2019;3(1):74–83. DOI: 10.1002/hep4.1285.
65. Santos-Marcos J.A., Rangel-Zuniga O.A., Jimenez-Lucena R. et al. Influence of gender and menopausal status on gut microbiota. Maturitas. 2018;116:43–53. DOI: 10.1016/j.maturitas.2018.07.008.
66. Liu Y., Lu J., Xu M. et al. Association between history of abortion and nonalcoholic fatty liver disease in middle-aged and elderly Chinese women. Ann Epidemiol. 2013;23:119–123. DOI: 10.1016/j.annepidem.2012.12.002.
67. Ajmera V., Terrault N.A., VanWagner L. et al. Longer lactation duration is associated with decreased prevalence of non-alcoholic fatty liver disease in women. J Hepatol. 2019;70:126–132. DOI: 10.1016/j.jhep.2018.09.013.
68. Hamaguchi M., Kojima T., Takeda N. et al. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med. 2005;143:722–728. DOI: 10.7326/0003-4819-143-10-200511150-00009.
69. Kojima S., Watanabe N., Numata M. et al. Increase in the prevalence of fatty liver in Japan over the past 12 years: Analysis of clinical background. J Gastroenterol. 2003;38:954–961. DOI: 10.1007/s00535-003-1178-8.
70. Park S.H., Jeon W.K., Kim S.H. et al. Prevalence and risk factors of non-alcoholic fatty liver disease among Korean adults. J Gastroenterol Hepatol. 2006;21:138–143. DOI: 10.1111/j.1440-1746.2005.04086.x.
71. Zhou Y.J., Li Y.Y., Nie Y.Q. et al. Prevalence of fatty liver disease and its risk factors in the population of South China. World J Gastroenterol. 2007:13:6419–6424. DOI: 10.3748/wjg.v13.i47.6419.
72. Koulouri O., Ostberg J., Conway G.S. Liver dysfunction in Turner's syndrome: Prevalence, natural history and e_ect of exogenous oestrogen. Clin Endocrinol (Oxf.) 2008;69:306–310. DOI: 10.1111/j.1365-2265.2008.03203.x.
73. Ascha M.S., Hanouneh I.A., Lopez R. et al. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology. 2010;51:1972–1978. DOI: 10.1002/hep.23527.
74. Klair J.S., Yang J.D., Abdelmalek M.F. et al. A longer duration of estrogen deficiency increases fibrosis risk among postmenopausal women with nonalcoholic fatty liver disease. Hepatology. 2016;64:85–91. DOI: 10.1002/hep.28514.
75. Lee C., Kim J., Jung Y. Potential Therapeutic Application of Estrogen in Gender Disparity of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis. Cells. 2019;8(10):1259. DOI: 10.3390/cells8101259.
76. Yoneda M., Thomas E., Sumida Y. et al. The influence of menopause on the development of hepatic fibrosis in nonobese women with nonalcoholic fatty liver disease. Hepatology. 2014;60:1792. DOI: 10.1002/hep.27097.
77. Klair J.S., Yang J.D., Abdelmalek M.F. et al. Nonalcoholic Steatohepatitis Clinical Research Network. A longer duration of estrogen deficiency increases fibrosis risk among postmenopausal women with nonalcoholic fatty liver disease. Hepatology. 2016;64(1):85–91. DOI: 10.1002/hep.28514.
78. European Heart Network. European Cardiovascular Disease Statistics 2017 edition. Brussels, Belgium: European Heart Network, 2017. DOI: 10.21820/23987073.2017.6.56.
79. Maas A.H.E.M., Rosano G., Cifkova R. et al. Cardiovascular health after menopause transition, pregnancy disorders, and other gynaecologic conditions: a consensus document from European Cardiologists, Gynaecologists, and Endocrinologists. Eur Heart J. 2021;42:967–984. DOI: 10.1093/eurheartj/ehaa1044.
80. Stevenson J.C., Collins P., Hamoda H. et al. Cardiometabolic health in premature ovarian insufficiency. Climacteric. 2021;24:474–480. DOI: 10.1080/13697137.2021.1910232.
81. Anagnostis P., Lambrinoudaki I., Stevenson J.C., Goulis D.G. Menopause-associated risk of cardiovascular disease. Endocr Connect. 2022;11(4):e210537. DOI: 10.1530/EC-21-0537.
82. Nadinskaia M., Maevskaya M., Ivashkin V. et al. Ursodeoxycholic acid as a means of preventing atherosclerosis, steatosis and liver fibrosis in patients with nonalcoholic fatty liver disease. World J Gastroenterol 2021;27(10):959–975. DOI: 10.3748/wjg.v27.i10.959.
83. Гаврилова Н.П., Селивёрстов П.В., Айрапетян М.С. и др. Урсодезоксихолевая кислота в комбинации с менопаузальной гормональной терапией корригирует метаболические нарушения у женщин в менопаузе с неалкогольной жировой болезнью печени. Экспериментальная и клиническая гастроэнтерология. 2019;168(8):77–81. DOI: 10.31146/1682-8658-ecg-168-8-77-81. [Gavrilova N.P., Seliverstov P.V., Ayrapetyan M.S. et al. Ursodeoxycholic acid in combination with menopausal hormone therapy corrects metabolic abnormalities in postmenopausal women with non-alcoholic fatty liver disease. Experimental and Clinical Gastroenterology. 2019;168(8):77–81 (in Russ.)]. DOI: 10.31146/1682-8658-ecg-168-8-77-81.
84. Gozukara I., Dokuyucu R., Özgür T. et al. Histopathologic and metabolic effect of ursodeoxycholic acid treatment on PCOS rat model. Gynecol Endocrinol. 2016;32(6):492–497. DOI: 10.3109/09513590.2015.1134478.
This work is licensed under a Creative Commons «Attribution» 4.0 License.
Previous article
Next article
Распечатать